## **NEONATAL**

## **MEROPENEM**

This document should be read in conjunction with this **DISCLAIMER** 

Restricted: Requires Microbiologist review within 24 hours of initiation

Presentation	Vial: 500mg					
Classification	Bactericidal carbapenem antibiotic.					
	Acts by interfering with bacterial cell wall synthesis. It is active against a broad spectrum of aerobic and anaerobic bacteria.					
Indication	Treatment of severe infections including intra-abdominal infections, meningitis and other infections where multi-resistant infections are suspected or proven.					
Dose	Intra-abdominal and NON-CNS infections IV:					
	Corrected gestational age	Postnatal age	Dose	Frequency		
	<32 weeks	<14 days	20mg/kg/dose	12 hourly		
	<32 weeks	≥14 days	20mg/kg/dose	8 hourly		
	≥32 weeks	<14 days	20mg/kg/dose	8 hourly		
	≥32 weeks	≥14 days	30mg/kg/dose	8 hourly		
	Meningitis IV:					
	Corrected gestational age	Postnatal age	Dose	Frequency		
	<32 weeks	<14 days	40mg/kg/dose	12 hourly		
	<32 weeks	≥14 days	40mg/kg/dose	8 hourly		
	≥32 weeks	All ages	40mg/kg/dose	8 hourly		

Dose Adjustment	Dose and frequency adjustment may be required in cases of impaired renal function.				
Monitoring	Renal function – urea and electrolytes.				
3	Full blood count with long term use.				
Guidelines & Resources	WNHS Policy: Antimicrobial Stewardship				
Compatible Fluids	Sodium chloride 0.9% (preferred) Glucose 5%				
Preparation	<u>IV:</u>				
	Available from CIVAS (KEMH & PCH). <u>Dilution for 50mg/mL Concentration</u>				
	Add 10mL of a suitable diluent to 500mg vial of meropenem Concentration is 500mg/10mL				
	Final concentration is 50 mg/mL				
	Dilution for 25mg/mL Concentration				
	Add 20mL of a suitable diluent to 500mg vial of meropenem  Concentration is 500mg/20mL  Final concentration is 25mg/mL				
	Discard reconstituted solution immediately after use				
Administration	IV Infusion:				
	Infuse over 30 minutes				
Adverse Reactions	Common: diarrhoea, nausea, vomiting, thrombophlebitis, rash, pruritus				
	Infrequent: urticaria, eosinophilia, thrombocytopenia, neutropenia, abnormal liver function tests				
	Rare: seizures				
Storage	Store vials at room temperature – below 25°C and protect from light				
Notes	Cross reactivity may occur in patients with a history or hypersensitivity reactions to penicillins, carbapenems or cephalosporins.  Each 1g of meropenem contains 3.92 mmol (90.2mg) of sodium				

## References

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2401. 2, p1292.

Lilley L, Legge D. Paediatric injectable guidelines. 5th ed. Melbourne (Victoria): The Royal Children's Hospital; 2016.

Australian Medicines Handbook. Meropenem. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2019 [cited 2019 September]. Available from: https://amhonline.amh.net.au/

MIMS Australia. DBL Meropenem for Injection. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2019 [cited 2019 September]. Available from: <a href="https://www.mimsonline.com.au">https://www.mimsonline.com.au</a>

Truven Health Analytics. Meropenem. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2017 [cited 2019 September]. Available from: <a href="https://neofax.micromedexsolutions.com/">https://neofax.micromedexsolutions.com/</a>

Society of Hospital Pharmacists of Australia. Meropenem. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2019 September]. Available from: http://aidh.hcn.com.au

Paediatric Formulary Committee. BNF for Children: 2019. London: BMJ Group Pharmaceutical Press; 2019.

Document owner:	Head of Department - Neonatology					
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate					
Date first issued:	December 2008	Version:	3.0			
Last reviewed:	September 2019	Next review date:	Sept 2022			
Endorsed by:	Neonatal Directorate Management Group	Date:	Sept 2019			
Standards Applicable:	NSQHS Standards:  1  Governance  3  Infection Control  4  Medication Safety;					
Printed or personally saved electronic copies of this document are considered uncontrolled.						

© Department of Health Western Australia 2019

Access the current version from the WNHS website.